You just read:

Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities

News provided by

Sensus Healthcare

Feb 12, 2019, 08:45 ET